Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Follow-On Biologics Deal Gives Brands 12 Years Of Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

A senate markup is scheduled for June 27 on legislation to create abbreviated BLA approval pathway.

You may also be interested in...



Generic Biologics Bill Still Has Good Chance For Enactment This Year – Waxman, Pallone

Key House legislators assure generics industry that they remain committed to generic biologics legislation, though PDUFA will move ahead without it.

Generic Biologics Bill Still Has Good Chance For Enactment This Year – Waxman, Pallone

Key House legislators assure generics industry that they remain committed to generic biologics legislation, though PDUFA will move ahead without it.

Follow-On Biologics Bill Clears Senate Cmte. With Stronger Language On Exclusivity Cap

Generic firms remain concerned that innovators would be able to "evergreen" their products through minor changes.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel